Drug Trial Radar · NCT05231668
Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)
Last checked: Nov 19, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
16
Actual
Start
Aug 25, 2022
Primary completion
Nov 12, 2024
Study completion Nov 12, 2024
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Feb 9, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
SAR439459 is a human anti-Transforming growth factor β (TGFβ) monoclonal antibody. This phase 1 clinical study investigates the safety, tolerability, and activity of a single dose of SAR439459 in adult participants with OI. Participants will receive a single IV dose of SAR439459 with safety, pharmacokinetic (PK), and pharmacodynamic (PD) assessments over 24 weeks. There will be up to 3 dose cohorts. In addition to safety, tolerability, and PK assessments, bone mineral density (BMD) will be evaluated by dual-energy Xray absorptimetry (DXA) scan and a series of blood biomarkers will be monitored to document pharmacodynamic effects of the single dose of SAR439459.
Conditions
- Osteogenesis Imperfecta
Interventions
SAR439459Drug
Powder for solution for infusion; IV infusion
PlaceboDrug
Solution for infusion; IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs)/treatment-emergent adverse events (TEAEs)Time frame: From baseline to Week 24
Locations
13 sites in 4 countries. Site status is shown where the registry gives one.
UCLA Health_Site Number: 8400006
Los Angeles, California
Yale University - Site Number:8400007
New Haven, Connecticut
Indiana University School of Medicine_Site Number: 8400002
Indianapolis, Indiana
Kennedy Krieger Institute_Site number 8400004
Baltimore, Maryland
Cincinnati Children's Hospital Medical Center Site Number : 8400010
Cincinnati, Ohio
Vanderbilt University Site Number : 8400011
Nashville, Tennessee
Baylor College of Medicine - Site Number:8400003
Houston, Texas
Westmead Hospital_Site Number :0360003
Westmead, New South Wales, Australia
Department of Medicine/ School of Clinical Sciences at Monash Health Monash University_246 Clayton Road_Site Number :0360002
Clayton, Victoria, Australia
Toronto general Hospital_Site Number :1240002
Toronto, Canada
Bone Research and Education Centre_Site Number :1240003
Oakville, Ontario, Canada
Hopital Edouard Herriot _Site Number :2500002
Lyon, France
Hopital Lariboisiere_Site Number :2500001
Paris, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.